ment appeared normal in these mutants (data not shown). These findings provide genetic evidence that Cre-mediated recombination was observed in the endothelium by E8 (see Supplemental Figure S1B on the Cell endocardial calcineurin is specifically required to regulate NFATc1 activity during valvular elongation and reweb site at http://www.cell.com/cgi/content/full/118/5/ 649/DC1). By E9, Cnb1 protein was undetectable in enmodeling. docardial cells, and NFATc1 protein in these cells was localized to the cytoplasm, consistent with a loss of Endocardial Calcineurin Regulates Valvular Morphogenesis through NFATc1 calcineurin phosphatase activity (data not shown). Cnb1 protein was eliminated at E10 in both the endocardium To define the site of action of NFATc1, we generated a transgenic mouse line expressing the ␥ isoform of wildand the endocardially-derived cushion mesenchyme, re- type NFATc1 in the endocardium using the Tie2 proshown). Viability of NFATc1 Ϫ/Ϫ mice was fully rescued (Supplemental Figure S2D) , indicating that NFATc1 moter (Tie2-NFATc1). Expressing NFATc1 in the endocardium rescued the valvular defects in NFATc1 Ϫ/Ϫ mice, functions specifically in the endocardium to regulate valve morphogenesis. In contrast, transgenic endocarresulting in well-formed semilunar and atrioventricular valves at E15.5 ( Figures 1M-1O) , birth, and P21 (data not dial expression of NFATc1 failed to rescue the valvular defects observed in mice deficient in endocardial Cnb1 mesenchymal transformation of endocardial cushions explanted from E9.5 embryos (20-25 somite pairs) (Fig-(Supplemental Figure S2E ). This result shows that calcineurin regulates NFATc1 function in the endocardium, ures 3C-3E). In contrast, CsA had no effect on the outgrowth of mesenchymal cells from endocardial cushions consistent with the cytoplasmic localization of NFATc1 in embryos lacking endocardial Cnb1.
explanted from E10.5 embryos (35-39 somites) after EMT had begun ( Figure 3E) Figures 3G and 3I ), similar to the Cnb1 null mutants to the time at which NFATc1 expression becomes re-(data not shown). In addition to cushion defects, the stricted to the cushion endocardium where valve formac2/c3/c4 mutants had abnormally thinned myocardium, tion occurs ( Figures 2M-2Q ). However, the endocardial consistent with a role of calcineurin/NFATc in myocarcalcineurin/NFATc1 has no role in the EMT, even though dial development and hypertrophy (Molkentin et al., NFATc1 is specifically expressed in the endocardial cells 1998). These data, coupled with the observation that undergoing this process (note the normal EMT in em-EMT occurred normally in embryos lacking Cnb1 or bryos lacking NFATc1 and endocardial Cnb1; Figure 3E NFATc1 in the endocardium, indicate that NFATc2/3/4 and Supplemental Figures S3A-S3C ). These observaact outside of the endocardium and function in the myotions raise the question of how EMT is controlled within cardium to direct EMT in the cushion area. We conclude the area of endocardial NFATc1 expression.
that Cnb1 regulates NFATc2/c3/c4 in the myocardium to induce mesenchymal transformation of the endocarMyocardial Calcineurin Signaling through dium overlying the cushions.
NFATc2/3/4 Is Essential for Endocardial-toMesenchymal Transformation
To study the role of calcineurin signaling in the transforMyocardial Calcineurin Signaling at E9 Suppresses the Production of a Soluble Factor mation process, we employed an in vitro EMT assay (Runyan and Markwald, 1983) . The E9 endocardial cushthat Inhibits Mesenchymal Transformation To define the period in which calcineurin/NFATc is reion, consisting of endocardial and myocardial cell layers, was dissected from the atrioventricular canal and exquired for EMT in vivo, we exposed developing embryos to CsA in utero at different stages. Embryos exposed to planted on a collagen gel ( Figures 3A and 3B ). Endocardial cells in the explants normally undergo mesenchymal CsA at E9 showed reduced EMT ( Figure 3J ). In contrast, embryos exposed to CsA at either E8 or E10 showed transformation, proliferate, and migrate into the collagen gel within 24-48 hr. Enumerating morphologically disnormal EMT in the cushion areas (data not shown). The differential sensitivity of E9 and E10 embryos to CsA tinct mesenchymal cells at 24-48 hr provides a semiquantitative assay of EMT and the proliferation/migrainjection parallels the differential effects of CsA on E9.5 and E10.5 cushion explants in vitro (see above), indicattion of mesenchymal cells. CsA completely inhibited ing that myocardial calcineurin signaling is crucial at E9 studied the ability of endocardial cushions derived from Cnb1 null embryos to control EMT of adjacent wild-type to initiate valve morphogenesis.
Work in the past has shown that myocardial cells cushions in culture. We found that Cnb1 null explants but not wild-type explants inhibited mesenchymal transproduce signals that induce the adjacent endocardial cells in the cushion to undergo mesenchymal differentiaformation in cocultured wild-type cushion explants (Figures 4D-4F ). In addition, wild-type cushion explants tion (Eisenberg and Markwald, 1995 ). This feature allowed us to study the interactions between sFlt, VEGF, and CsA/ To identify the soluble inhibitor of EMT, we defined genes regulated by calcineurin/NFATc signaling at E9.5 FK506 in the embryo culture system. Embryos cultured at E9.5 developed normally for at using transcript arrays. Several secreted factors were derepressed in calcineurin or NFATc mutant mice and least 24 hr and underwent normal EMT in the whole embryo culture system ( Figure 5A ). As expected, CsA/ were derepressed by CsA administration. One of the candidates was vascular endothelial growth factor FK506 inhibited EMT in embryos cultured from E9.5 to E10.5 ( Figure 5B ). VEGF, similar to the calcineurin inhibi-(VEGF) (Graef et al., 2001 ). Given that transgenic overexpression of VEGF in myocardium at E9 inhibits EMT (Dor tors, inhibited this transformation process, leaving the endocardial cushion devoid of mesenchymal cells (Figet al., 2001) Figures 4G-4J) . It also rescued EMT in explants with Cnb1 null mutation not secondary to growth delay caused by angiogenic defects in the yolk sac/embryos since no such defects ( Figure 4K ). In contrast, TGF-␤3, a signal essential for EMT, did not reverse the effect of CsA or Cnb1 mutation were observed when embryos were treated with CsA/ FK506 from E9.5 to E10.5 (data not shown). This is con-(data not shown), suggesting that the action of sFlt was specific for calcineurin/NFATc. Similar to CsA, VEGF sistent with the previous report that calcineurin is required for angiogenesis between E7 and E8 (Graef et al., strongly inhibited EMT of the E9.5 cushion explants but did not have a significant effect on the proliferation or 2001). Therefore, these data provide additional in vivo evidence that suppression of myocardial VEGF producmigration of mesenchymal cells of E10.5 explants (Figure 4L) . Inhibition of EMT by VEGF was reversed by sFlt tion by calcineurin is essential to initiate EMT in intact embryos. in a dose-dependent manner ( Figure 4M and data not shown). Similarly, sFlt rescued CsA-inhibited EMT (Figure 4N) , indicating that CsA's effect on EMT was mediCalcineurin Control of VEGF Is Conserved in Fish Heart Valve Morphogenesis ated through VEGF. To further study the role of VEGF at physiological levels, we added 0.2 nM sFlt to normal To study whether the requirement for calcineurin signaling in heart valve development is conserved across evo-E9 cushion explants, fully blocking endogenous VEGF signaling. We found that this higher dose of sFlt enlution, we performed FK506 treatment and washout experiments on zebrafish. We found that calcineurin was hanced EMT by 2-to 3-fold ( Figure 4N ), suggesting that VEGF was functioning at physiologic levels in the cushmost crucial for heart valve formation between 22 and 30 hpf in the zebrafish embryos ( Figures 5G and 5H ). ion to keep EMT in check. These data indicate that calcineurin/NFATc signaling normally suppresses VEGF Zebrafish treated with CsA/FK506 between 22 and 30 hpf developed congestive heart failure with swelling of in the cushion to allow endocardial-mesenchymal transformation.
pericardial sacs (Figures 5H-5K was also required in zebrafish for heart valve formation, with the gestational age of the embryos from E10 to E12 (data not shown). In contrast, VEGF was strongly we performed rescue experiments using sFlt to antagonize VEGF activity. Indeed, sFlt rescued valvular defects expressed in the myocardium of Cnb1-deficient E9.0 embryos ( Figure 6E Figure 6I ). CsA also increased embryos. We found that endocardial cushion explants VEGF protein expression in E9 embryonic hearts cultreated with CsA in vitro had highly elevated VEGF tured on collagen gel ( Figure 6J ). Embryos exposed to mRNA expression in the myocardium compared to conCsA in utero also had elevated VEGF expression by trols (Figures 6A-6C) . CsA, by inhibiting calcineurin/ RNAase protection assay, transcript array analysis NFATc activity, was therefore capable of derepressing (Graef et al., 2001) , and ELISA analysis ( Figure 6J ), sug-VEGF mRNA levels in the myocardium, suggesting a gesting that CsA derepressed VEGF expression in utero. repressor function of NFATc in the regulation of VEGF These observations indicate that calcineurin and NFATc expression. In wild-type mice, myocardial VEGF expressignaling suppress VEGF production and led us to invession was low at E9.0 of development ( Figure 6D) , when tigate the mechanism of this repression.
EMT was most sensitive to the inhibition by CsA or
To study the molecular basis underlying the repres-VEGF. VEGF expression became detectable in the myosion of VEGF by calcineurin/NFATc, we sought a cell cardium by early E10 (data not shown), at a time after culture system that would closely reflect the derepres-EMT had taken place and cushion mesenchymal cells sion of VEGF observed in embryos deficient in this pathwere refractory to the effect of CsA or VEGF. VEGF expression subsequently increased in the myocardium way. We found that treatment of primary mouse embry- weakly detectable (data not shown). The IL-2 promoter NFAT site, which is not active in MEFs, was not precipibound recombinant NFATc3 and c4 proteins ( Figure 7C,  lanes 1 and 6) . The observed complexes contained tated by anti-NFATc4 antibody ( Figure 7F ), indicating that endogenous NFAT complexes form specifically on NFATc proteins as they were supershifted with an antibody recognizing the protein ( Figure 7C, lanes 2 and 7) . the mϪ2400 site of the VEGF promoter. Taken together, these data suggest that endogenous calcineurin/NFATc The formation of NFATc3-DNA complexes was disrupted by an excess of unlabeled competitor oligo directly represses the transcription of the VEGF-A gene. (mϩ3243, mϪ2400) ( Figure 7C, lanes 3 and 8) but not by excess competitor oligo with GGAAA to GGAGC muDiscussion tation in the core sites (mϩ3243 mut, mϪ2400 mut) ( Figure 7C, lanes 4 and 9) . This GGAGC core site mutaDuring early heart development, the primitive endocardial cushion serves as a valve because the primary myotion reduced NFATc3 binding ( Figure 7C, lanes 5 and  10) . None of the other nine candidate sites, such as cardium surrounding the cushion contracts rhythmically to occlude the heart lumen during the cardiac cycle to m-1592, was bound by NFATc3 ( Figure 7C , lane 11, and data not shown). NFATc3 bound at subnanomolar prevent blood reflux (Moorman et al., 1998) . This early primitive valve function is calcineurin independent, as concentrations to the VEGF-A mϪ2400 site with substantially higher affinity than the canonical NFAT site in embryos lacking calcineurin have normal sequential atrial ventricular contraction and unidirectional flow the IL-2 promoter (mIL2) (Shaw et al., 1988) (Figure 7D ). NFATc3 bound the mϩ3243 site at an affinity comparawithout blood regurgitation (data not shown). As the heart enlarges during development, the rhythmic conble to mIL2 site binding, suggesting that the binding of NFATc3 to these sites is specific and strong enough to tractions of primitive cushions are insufficient to occlude the heart lumen. At this point, valve development is be physiologically relevant.
We defined the regions of the VEGF gene mediating essential, and a requirement of calcineurin/NFAT signaling becomes apparent. CsA-and NFATc4-dependent repression using luciferase reporter assays in MEFs. Transfection of a constitutively nuclear/active form of NFATc4 (c4 ., 1999) . Therefore, the crease (2-to 3-fold) in endogenous VEGF expression endocardial cushion and adjacent myocardium constileads to embryonic lethality at midgestation due to abtute a morphogenetic unit (blue area in Figure 7G ) that normal myocardial development and defective septal gives rise to heart valves. Our studies indicate that NFAT formation (Miquerol et al., 2000) . Our findings indicate signaling operates within this morphogenetic unit, first that NFAT signaling directly suppresses VEGF expresin the myocardium and then in the endocardium to consion in the heart at the initial phase of heart valve mortribute to the formation of heart valves ( Figure 7G ). This phogenesis when VEGF is widely expressed elsewhere mechanism is also conserved in zebrafish, illustrating for embryonic angiogenesis and other developmental the importance of NFAT signaling in vertebrate heart processes (Miquerol et al., 1999) . valve development. Why should a field of calcineurin/NFATc function in adjacent tissues be essential to both initiate and propaRefinement of Heart Valve Morphogenesis Requires Endocardial but Not Mesenchymal gate morphogenesis of heart valves? One possibility is that there are two distinct signals that sequentially Calcineurin/NFATc Signaling Remodeling the heart valve leaflets requires signaling activate first myocardial and then endocardial NFATc at specific times of valve development. Alternatively, a interactions between the endocardial cells and underlying mesenchymal cells. Our studies demonstrate that "master" signal may activate myocardial NFATc leading to VEGF repression and the transcription of a secreted endocardial calcineurin/NFATc1 is required at E11 to direct heart valve elongation. In contrast, autonomous molecule that in turn activates endocardial NFATc1. In this second mechanism, only one signal is required to calcineurin/NFATc signaling in the cushion mesenchyme may not contribute significantly to the remodelorder the sequence of NFATc signaling for valve formation. The initial signal could be provided by Wnt and/or ing process, based on the following observations. First, expressing NFATc1 in the endocardial cells of NFATc1 Ϫ/Ϫ mechanical cues resulting from hemodynamic stress as the embryo develops. A third possibility is that local mice completely rescued the valvular defects, indicating that NFATc1 in the cushion mesenchyme is not essential production of a soluble, membrane-permeable molecule (blue area in Figure 7G ) regulates an NFAT nuclear partfor valve remodeling. This is further supported by the observation that NFATc1 proteins became inactivated ner protein (NFATn) ( Figure 7H ). Since NFAT activity depends on activation of both NFATc and NFATn, such and exported to the cytoplasm as the endocardial cells delaminated from the surface during EMT (Supplemena mechanism could specifically coordinate NFAT function in two adjacent tissues. tal Figure S1E) , and the expression of NFATc1 was rapidly repressed as the mesenchymal cells migrated into How do the requirements for NFAT signaling relate to other known requirements for heart valve formation? the cushion (Supplemental Figure S1E) Figure S1D ) displayed valvular defects identical to mice lacking NFATc1, which is active only (Hurlstone et al., 2003) . Hence, Wnt signaling could act upstream of NFATc2/c3/c4. in the endocardium. This suggests that calcineurin in the mesenchyme makes no additional contribution to A major goal of modern developmental biology is the recapitulation of development for regenerative or theraheart valve remodeling. Third, embryos exposed to CsA in utero (Figure 2 ) had valvular defects almost identical peutic purposes. Since heart valve malformations are the most common human congenital abnormalities, this to mice lacking endocardial Cnb1 or NFATc1, suggesting that myocardial or mesenchymal Cnb1 does not congoal is particularly salient. 
